Corbevax, the Biological E’s COVID-19 vaccine, has been cleared for booster dose for those 18 and above. The company, in a statement today, said that it can be administered to people six months after they have taken the primary two doses of either Covaxin or Covishield for restricted use in emergency situation. Corbevax thereby becomes India’s first heterologous Covid booster.
Mahima Datla, the Managing Director of Biological E, said in a statement today: “We are very happy with this approval, which will address the need for COVID-19 booster doses in India. We have crossed yet another milestone in our COVID-19 vaccination journey. This approval reflects once again the sustained world class safety standards and high immunogenicity of Corbevax.”
The company added that when compared to placebo, the booster dose of Corbevax increased the neutralizing antibody titers – or a measurement of the amount or concentration of a substance in a solution – in the Covishield and Covaxin groups significantly.
The DCGI, drug regulator of India, had given emergency use authorisation (EUA) to Corbevax for children between 5 and 12 years in late April.
The vaccine manufacturer also reduced the price of Corbevax to ₹ 250 from ₹ 840 a dose, including GST, for private vaccination centres in May.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
